MOLN stock forecast, quote, news & analysis
Molecular Partners AG is a clinical stage biopharmaceutical company... Show more
Why Molecular Partners (MOLN) Stock Is Down -13% in the Last 30 Days
Key Takeaways
- Molecular Partners (MOLN) shares declined roughly 13% over the past 30 days, falling from about $3.91 in early October to approximately $3.40.
- The pullback extends a longer downtrend: the stock is down roughly 16% over the most recent quarter, from around $4.07 in early August.
- Third-quarter 2026 results, released on October 29, deepened the company's strategic focus on radiotherapeutics and included a restructuring of up to roughly 44% of positions.
- Pipeline momentum continued despite the share decline, including the nomination of MP0730 (targeting CD70) as the third Radio-DARPin program and ongoing MP0712 dose escalation.
- Cash and cash equivalents stood at CHF 57.5 million (about USD 69 million) as of September 30, 2026, expected to fund operations into late 2027.
- Analyst coverage remains constructive, with Clear Street maintaining a Buy rating and an $8 price target on the shares.
- For additional detail on this ticker, explore its Price Targets, Earnings, and Forecast pages to review valuation, results, and forward-looking estimates.
- Readers can also monitor automated trading strategies and market signals through Trending AI Robots.
Molecular Partners (MOLN) Company Overview and Market Position
Molecular Partners AG is a Swiss clinical-stage biotechnology company that designs and develops a novel class of medicines known as DARPin (Designed Ankyrin Repeat Protein) therapeutics. The company is increasingly focused on targeted radiotherapeutics, using its Radio-DARPin platform as an isotope-agnostic vector to deliver radioactive payloads selectively to tumor lesions while sparing healthy tissue.
Its lead candidate, MP0712, targets DLL3 and carries the alpha-emitting isotope 212Pb; it is being co-developed with Orano Med for small cell lung cancer and other neuroendocrine cancers. The pipeline also includes MP0726 (targeting MSLN) and MP0730 (targeting CD70), along with earlier-stage immune cell engagers. With no approved products, the company generates revenue through collaborations, milestones, and research payments. Investors follow the stock primarily for its clinical data readouts, cash runway, and progress in the growing radiopharmaceutical sector.
Molecular Partners (MOLN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MOLN shares have moved lower, falling from a closing level of approximately $3.91 in early October to around $3.40, a decline of roughly 13%. The move was gradual rather than abrupt, unfolding across a period of relatively light trading volume characteristic of a small-cap, pre-revenue biotech.
The broader trend has been similarly negative. Measured from early August, when the stock traded near $4.07, the shares have declined roughly 16% over the most recent quarter. The stock has spent much of this period drifting within a lower range, reflecting limited near-term catalysts and a market that has been slow to reward the company's ongoing pipeline execution.
What Drove MOLN Stock Price in the Last 30 Days
Several factors shaped the recent decline. On October 29, the company reported third-quarter 2026 results and announced a deepened strategic focus on radiotherapeutic medicines. As part of that shift, Molecular Partners said it intends to streamline its organization and reduce its workforce by up to 55 positions, representing up to roughly 44% of roles, with full implementation expected by the second quarter of 2027.
Positive clinical news did not fully offset the market's reaction. Earlier in the month, the company nominated MP0730, a CD70-targeting Radio-DARPin, as its third radiotherapeutic program, and reported that its lead candidate MP0712 continued dosing in dose level 2 of its Phase 1/2a study with no dose-limiting events observed to date. However, with efficacy data for MP0712 not expected until 2027, investors have had limited near-term catalysts to bid the stock higher, and the shares drifted lower on modest volume.
What Drove MOLN Stock Performance Over the Last Quarter
The quarterly decline reflects a broader narrative of strategic repositioning. Over the past three months, Molecular Partners has sharpened its identity as a dedicated radiopharmaceutical company, prioritizing MP0712 and its expanding Radio-DARPin pipeline while signaling that it will explore partnerships and spin-out opportunities for non-core assets.
At the same time, the company's cash position tightened as it continued investing in clinical development. The combination of a restructuring announcement, a longer wait for efficacy data, and limited revenue has weighed on sentiment, even as the underlying clinical program advanced. The result has been a steady downward drift rather than a single-event sell-off.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of top-performing and most relevant AI trading bots from a broader ecosystem of hundreds of automated strategies that monitor thousands of tickers. These bots vary in strategy, timeframe, and performance metrics, allowing users to review approaches that range from short-term momentum signals to longer-horizon trend models. The curated list is designed to surface the strategies currently drawing the most attention and relevance in the market. Investors interested in systematic, data-driven trading can explore the Trending AI Robots page to see which automated strategies are generating signals across the market.
MOLN Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for Molecular Partners center on its clinical pipeline. Initial safety data from the Phase 1/2a study of MP0712 is expected to be presented at the IASLC/ASCO North America Conference on Lung Cancer in December 2026, with efficacy data anticipated in 2027. Progress on MP0726 toward first-in-human imaging and the expected start of a first-in-human program for MP0730 in 2027 are additional milestones to monitor.
Investors should also track the execution and financial impact of the restructuring, the company's cash runway into late 2027, and any updates on collaborations and strategic partnerships. As with all clinical-stage biotechs, regulatory developments, trial outcomes, and broader biotech sector sentiment will continue to influence the stock. This information is provided for context and is not a recommendation to buy or sell any security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for MOLN turns negative, indicating new downward trend
MOLN saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 129 similar instances where the indicator turned negative. In 105 of the 129 cases, the stock moved further down in the following days. The odds of a decline are at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for MOLN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 47 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for MOLN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MOLN's RSI Indicator exited the oversold zone, 22 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOLN advanced for three days, in 131 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
MOLN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.054) is normal, around the industry mean (3.498). P/E Ratio (-2.326) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (158.730) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. MOLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology